The tender titled Inj Tocilizumab 400 mg under reference number a222bdb7 is issued by the Ministry of Labour and Employment. This tender aims to procure Inj Tocilizumab 400 mg, a critical medication used in the treatment of various diseases including but not limited to moderate to severe rheumatoid arthritis, systemic juvenile idiopathic arthritis, and COVID-19 related complications.
Scope of Work and Objectives
The primary objective of this tender is to ensure a consistent and adequate supply of Inj Tocilizumab 400 mg to various healthcare institutions under the ministry's jurisdiction. The contracted suppliers will be responsible for providing a total quantity of six units of this vital medication. The scope includes:
- Providing high-quality Inj Tocilizumab 400 mg as per the specified technical requirements.
- Ensuring timely delivery to designated healthcare facilities.
- Complying with all applicable health regulations and standards.
Eligibility Criteria
To qualify for this tender, bidders must:
- Be a registered pharmaceutical supplier or manufacturer with the necessary licenses.
- Meet all regulatory and compliance requirements set forth by health authorities.
- Provide documentation verifying their capability to supply the required quantity and quality of the medication.
Technical Requirements
Bidders are required to adhere strictly to technical specifications including:
- Quality standards mandated by regulatory bodies for medical supplies.
- Packing and labeling regulations ensuring proper storage and use.
- Evidence of previous successful supply of similar medications may bolster a bidder's proposal.
Financial Requirements
Intent to participate in this tender mandates financial verification, notably:
- Provision of a bank guarantee or Earnest Money Deposit (EMD) to secure the bid.
- Disclosure of applicable financial statements to demonstrate the financial stability of the bidding organization.
Document Submission Details
All proposals must be prepared according to submission guidelines detailed in the tender documentation. This includes submission formats, necessary certifications, and compliance documents which must be submitted through an electronic portal provided by the Ministry.
Special Provisions
This tender encourages participation from Micro, Small, and Medium Enterprises (MSEs) and startups by offering specific benefits. These may include:
- Relaxed eligibility criteria which allow smaller businesses to compete effectively.
- Priority in evaluations aimed at enhancing local supplier participation.
Evaluation Process
The evaluation process will consist of a thorough review of all submitted documents and proposals. Key considerations include:
- Compliance with technical and financial requirements.
- Previous experience in supplying similar products.
- Price evaluation considering both the offered rates and the quality of products.
Delivery Locations
The Inj Tocilizumab 400 mg will be required at specified healthcare facilities determined by the Ministry. Exact delivery locations will be communicated to successful bidders upon contract awarding.
Contact Information
For any inquiries regarding this tender, interested parties can reach out to the relevant point of contact listed in the official tender documents. All communications should maintain professionalism and clarity.
In summary, this tender for Inj Tocilizumab 400 mg represents a significant opportunity for suppliers who meet the outlined criteria and possess the capability to deliver high-quality medical products. Participation not only supports healthcare initiatives but also empowers local businesses in the pharmaceutical industry.
General Information
Financial Information
Evaluation and Technical Information
Tender Documents
3 DocumentsDocuments Required from Seller
- Experience Criteria
- Past Performance
- Bidder Turnover
- OEM Authorization Certificate
- OEM Annual Turnover *In case any bidder is seeking exemption from Experience / Turnover Criteria
- the supporting documents to prove his eligibility for exemption must be uploaded for evaluation by the buyer
Similar Tenders
Frequently Asked Questions
The eligibility requirements include being a registered pharmaceutical supplier or manufacturer with valid licenses. Suppliers must also comply with all pertinent regulations and provide documentation that verifies their capability to deliver the required quantity and quality of Inj Tocilizumab 400 mg. It is essential that businesses have a track record of supplying similar medications to meet the tender’s standards.
Bidders must submit valid certificates demonstrating regulatory compliance including manufacturing licenses for pharmaceuticals, quality assurance certifications, and any other relevant documents that confirm the ability to produce and supply Inj Tocilizumab 400 mg. These certificates are crucial for ensuring adherence to quality standards.
The Earnest Money Deposit (EMD) must be submitted alongside the bid documents to secure participation in the tender. The amount will be defined in the tender document. It acts as a security measure to ensure that only serious bidders are considered and will be refunded after the contract awarding process, unless otherwise specified.
Bidders must adhere to the specified submission formats outlined in the tender documentation. Typically, documents should be submitted in PDF or Word formats to maintain clarity and accessibility. It is essential to follow the prescribed guidelines to ensure compliance with the evaluation process.
Micro, Small, and Medium Enterprises (MSEs) are encouraged to participate in this tender through various provisions that include relaxed eligibility criteria and preference in the selection process. This initiative aims to strengthen local supplier networks and promote inclusive economic growth within the pharmaceutical sector. MSEs contributing to the local economy may also find related benefits through government policies supporting Make in India initiatives.
Probable Bidders
Get Tender Alerts
Get notifications for similar tenders